Sun Pharma v. Orexo: Federal Circuit Appeal Dismissed After 494 Days
Sun Pharmaceuticals and its affiliates voluntarily dismissed their Federal Circuit appeal against Orexo AB over nine patents covering buprenorphine/naloxone sublingual film formulations. The motion, filed under Fed. R. App. P. 42(b), was granted with each side bearing its own costs — leaving the underlying patent landscape unresolved on the merits.
Sun Pharma exits Federal Circuit appeal without a merits ruling on Orexo’s sublingual film patents
Sun Pharmaceuticals Industries Ltd., Sun Pharma Global Inc., and Sun Pharma Global FZE (collectively, Sun) filed this Federal Circuit appeal on 11 August 2023, challenging Orexo AB and Orexo US Inc. in an infringement action centred on nine US patents protecting buprenorphine/naloxone sublingual film formulations. Sun’s ANDA products — spanning five dosage strengths from 1.4/0.36 mg to 11.4/2.9 mg — were the commercial target of the underlying litigation, consistent with the Hatch-Waxman ANDA pathway typically at issue in generic pharmaceutical challenges.
On 17 December 2024, the Federal Circuit granted Sun’s motion to dismiss the appeal under Fed. R. App. P. 42(b), with each side bearing its own costs. The dismissal is procedural rather than substantive: no appellate merits ruling was issued on claim validity, infringement, or enforceability of any of the nine asserted patents. The public record does not specify whether the dismissal reflects a settlement, a commercial decision by Sun, or a change in ANDA strategy — all of which are plausible explanations.
A 494-day appellate proceeding ending in voluntary dismissal — rather than a Federal Circuit judgment — suggests the commercial or legal calculus shifted for Sun during the appeal. Whether a confidential settlement was reached, Sun’s ANDA pathway was abandoned, or some other strategic factor intervened is not discernible from the public record. Orexo’s nine patents remain unchallenged on the merits at the appellate level, which typically strengthens their enforceability posture against future generic entrants in the buprenorphine/naloxone sublingual segment.
Filing to Case Dismissed in 494 days
494-day appeal duration before voluntary dismissal under Fed. R. App. P. 42(b)
Appeal voluntarily dismissed: what the termination means for both parties
Fed. R. App. P. 42(b) dismissal: no merits adjudication
Rule 42(b) allows an appellant to voluntarily dismiss an appeal at any time before decision. The Federal Circuit’s order here is purely procedural — it does not affirm, reverse, or vacate any lower-court finding on validity or infringement. The nine Orexo patents were never assessed on the merits at the appellate level, leaving the legal record below as the operative outcome.
No merits ruling issuedWith or without prejudice? The public record is silent
The court order states dismissal under Rule 42(b) with each side bearing own costs, but does not specify with or without prejudice. A voluntary appellate dismissal under Rule 42(b) does not automatically bar future challenges — Sun could potentially re-engage via IPR or a new ANDA litigation — but the precise preclusive effect depends on the terms of any underlying agreement, which are not publicly available.
Preclusive scope unclearSun exits appeal without securing a validity ruling
For Sun Pharmaceuticals, the dismissal means its ANDA product line at the five contested dosage strengths remains commercially blocked absent a separate invalidity finding or licensing arrangement. The decision to withdraw after 494 days of appellate proceedings suggests a significant strategic recalibration — though whether driven by commercial negotiation, resource allocation, or ANDA reformulation is not discernible from the public record.
ANDA pathway remains blockedOrexo retains all nine patents unchallenged at appeal
Orexo AB and Orexo US Inc. emerge from this proceeding with their nine-patent portfolio intact at the appellate level. No claim was invalidated, and no adverse merits finding was made. This outcome typically strengthens the deterrent value of the portfolio against future generic challengers, though any prospective ANDA filer retains the ability to mount fresh IPR petitions or paragraph IV challenges on independent grounds.
Patent portfolio survives appealFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Sun Pharmaceuticals Industries, Ltd. | Company | Generic pharmaceutical group pursuing ANDA entry into buprenorphine/naloxone sublingual film marketSearch in Eureka ↗ |
| Co-Plaintiff | Sun Pharma Global, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Sun Pharma Global FZE | Individual | Search in Eureka ↗ |
| Defendant | Orexo, AB | Individual | Specialty pharma company holding nine US patents on buprenorphine/naloxone sublingual film formulationsSearch in Eureka ↗ |
| Co-Defendant | Orexo US, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles B. Klein | Attorney | Counsel for Sun Pharmaceuticals Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Claire A. Fundakowski | Attorney | Counsel for Sun Pharmaceuticals Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Eimeric ReigPlessis | Attorney | Counsel for Sun Pharmaceuticals Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jovial Wong | Attorney | Counsel for Sun Pharmaceuticals Industries, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Winston & Strawn, LLP | Law Firm | Representing Sun Pharmaceuticals Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | John J. Molenda | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant counsel | Jordan P. Markham | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant counsel | Lawrence T. Kass | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant counsel | Michael I. Green | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant counsel | Vishal C. Gupta | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant counsel | Yun Zhang | Attorney | Counsel for Orexo, ABSearch in Eureka ↗ |
| Defendant law firm | Steptoe, LLP | Law Firm | Representing Orexo, ABSearch in Eureka ↗ |
| Presiding judge | Judge Georgette Castner | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is confined to granting the procedural dismissal motion under Fed. R. App. P. 42(b) — it makes no finding on the validity, enforceability, or infringement scope of any of Orexo’s nine asserted patents. The own-costs provision is neutral and does not signal a prevailing party. Because no merits judgment was rendered, the order creates no claim preclusion or issue estoppel on patent validity, preserving Sun’s theoretical ability to challenge the same patents through IPR or future ANDA litigation on independent grounds.
US8940330B2 and eight further Orexo patents — buprenorphine/naloxone sublingual film
The nine asserted patents — US8940330B2, US9259421B2, US8470361B2, US10874661B2, US11020387B2, US10946010B2, US11020388B2, US9439900B2, and US8658198B2 — collectively protect Orexo’s buprenorphine/naloxone sublingual film technology, which is the active ingredient platform underlying branded opioid use disorder treatments. The application families span filings from the early 2010s through to the late 2010s, suggesting a prosecution strategy designed to extend meaningful patent coverage across successive formulation and method-of-use innovations in this therapeutic area.
The breadth and density of this nine-patent portfolio is commercially significant in the Hatch-Waxman context: each patent represents an independent barrier to generic ANDA approval, and Orexo’s layered coverage of composition, method, and dosage unit claims is consistent with a deliberate effort to create interlocking protection. For any generic manufacturer targeting buprenorphine/naloxone sublingual film, the portfolio presents a complex freedom-to-operate challenge — particularly given that no patent was invalidated or narrowed in this proceeding.
Should you run an FTO analysis against Orexo’s buprenorphine/naloxone patent portfolio?
Any pharmaceutical company with active or planned ANDA filings for buprenorphine/naloxone sublingual film products should treat Orexo’s nine-patent portfolio as a live enforcement risk. The voluntary dismissal in this case does not extinguish any patent — all nine remain in force. R&D and regulatory teams developing generic sublingual buprenorphine/naloxone products at the five dosage strengths implicated by Sun’s ANDA should commission a current FTO before investing further in clinical, manufacturing, or regulatory infrastructure.
PatSnap Eureka’s FTO Search Agent can map each of the nine Orexo patent families against your product specifications, identify claim-by-claim infringement risk at the specific dosage strengths, surface relevant prior art for potential IPR petitions, and flag expiry dates across the portfolio. This structured analysis is essential before paragraph IV certification decisions and supports both litigation risk assessment and licensing strategy in the buprenorphine/naloxone sublingual film segment.
Run a freedom-to-operate analysis on US8940330B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA appeals in buprenorphine/naloxone and sublingual drug delivery
Related Federal Circuit cases involving Hatch-Waxman ANDA challenges to buprenorphine/naloxone sublingual film patents and comparable generic pharmaceutical infringement appeals.
What this case signals for the buprenorphine/naloxone generic IP landscape
A voluntary Federal Circuit dismissal after 494 days without a merits ruling carries meaningful signals for generic pharma strategy and Hatch-Waxman litigation planning.
Voluntary appellate dismissal strengthens Orexo’s patent deterrence posture
When a generic challenger withdraws a Federal Circuit appeal without a validity ruling, the patentee’s portfolio emerges operationally stronger. No claim was cancelled or narrowed. For competitors monitoring buprenorphine/naloxone sublingual film, Orexo’s nine-patent cluster now carries an additional layer of unadjudicated validity — raising the risk calculus for the next ANDA filer.
Nine-patent coverage across multiple US application families creates staggered expiry risk
Orexo’s asserted portfolio spans nine distinct US patent numbers across separate application families, suggesting layered protection that generic challengers must navigate sequentially. Even if one patent is invalidated in a future IPR, the remaining eight continue to block commercial entry. Any generic entrant targeting this market should map expiry dates and claim scope across all nine before committing to ANDA investment.
Sun v Orexo — key questions answered
Sun Pharmaceuticals and its affiliates voluntarily dismissed their Federal Circuit appeal (Case 23-2273) against Orexo AB on 17 December 2024, pursuant to Fed. R. App. P. 42(b). The court granted the motion with each side bearing its own costs. No merits ruling was issued on any of the nine asserted buprenorphine/naloxone patents.
Orexo asserted nine US patents: US8940330B2, US9259421B2, US8470361B2, US10874661B2, US11020387B2, US10946010B2, US11020388B2, US9439900B2, and US8658198B2. These patents collectively cover buprenorphine/naloxone sublingual film formulations across multiple dosage strengths targeted by Sun’s ANDA.
A Rule 42(b) voluntary dismissal of an appeal does not itself generate claim preclusion or issue estoppel on patent validity because no merits judgment was rendered. Sun or a third party would likely retain the ability to petition for inter partes review of Orexo’s nine patents. The preclusive effect of any underlying settlement agreement, however, is not determinable from the public record.
The own-costs provision means neither party is entitled to recover appellate costs from the other. It is a neutral cost allocation commonly used in voluntary dismissals and does not signal a prevailing party. It does not address attorney fees or any lower-court cost awards, and it carries no inference about the merits of the underlying patent dispute.
The dismissal does not itself grant Sun any right to launch. Orexo’s nine patents remain in force and unchallenged on the merits at the appellate level. Sun’s ANDA products at the five asserted dosage strengths remain commercially blocked unless Sun obtains FDA approval unencumbered by patent term, secures a licence from Orexo, or successfully invalidates the relevant patents through a separate IPR or litigation proceeding.
PatSnap Eureka searches patents and litigation data to answer instantly.